Ignite Creation Date:
2024-05-06 @ 6:30 PM
Last Modification Date:
2024-10-26 @ 2:49 PM
Study NCT ID:
NCT05681039
Status:
RECRUITING
Last Update Posted:
2024-06-04
First Post:
2022-12-15
Brief Title:
Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma OCSCC
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Squamous Cell Carcinoma |
| Oral Cavity Squamous Cell Carcinoma |
Keywords: